Fifth Third Wealth Advisors LLC Acquires 149 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fifth Third Wealth Advisors LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 984 shares of the company’s stock after acquiring an additional 149 shares during the quarter. Fifth Third Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $407,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of IDXX. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC grew its position in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares during the period. Strategic Investment Solutions Inc. IL bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $36,000. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $37,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.18% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on IDXX. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler reiterated a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $539.63.

IDEXX Laboratories Trading Up 1.3 %

NASDAQ:IDXX opened at $428.62 on Friday. The company has a market cap of $35.10 billion, a P/E ratio of 41.33, a price-to-earnings-growth ratio of 3.52 and a beta of 1.36. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The business has a 50 day moving average price of $423.97 and a two-hundred day moving average price of $458.74. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same quarter in the prior year, the company posted $2.53 earnings per share. The firm’s revenue was up 6.6% on a year-over-year basis. As a group, analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.